Zoey Becker is a Staff Writer for Fierce Pharma, a leading publication in the pharmaceutical industry. With a focus on providing timely and insightful coverage, Zoey's articles delve into the latest developments, mergers and acquisitions, legal battles, and regulatory updates in the pharmaceutical and biotech sectors.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Zoey's coverage predominantly focuses on the healthcare and pharmaceutical industry, particularly on legal developments, mergers and acquisitions, drug development, and patent disputes. The majority of her articles are driven by press releases and government announcements.
For effective outreach to Zoey Becker, consider providing insights into ongoing legal battles in the pharmaceutical industry or exclusive information related to major mergers and acquisitions within the sector. Additionally, experts with knowledge about regulatory changes impacting drug development or those who can provide analysis based on credible data could be valuable sources for Zoey's reporting.
Given that her coverage attributes include a significant percentage of press releases as sources of information, she might also be interested in receiving embargoed news or early access to upcoming announcements within the healthcare and pharmaceutical space.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Zoey Becker, Darren Incorvaia
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry.
Thursday's appointment from president-elect Donald Trump made it official: noted vaccine skeptic Robert Francis Kennedy Jr. (RFK Jr.) will be asked to serve as the next U.S. secretary of the Department of Health and Human Services (HHS).
Months after filing for bankruptcy, VBI Vaccines is taking the next step in shuttering operations with the voluntarily withdrawal of its hepatitis B vaccine, PreHevbrio.
By: Zoey Becker
Robert F. Kennedy Jr.'s nomination as the Trump administration's HHS secretary has rocked the biopharma world, sending shares sinking for many drugmakers following the Thursday announcement.
By: Zoey Becker
Roche's spinal muscular atrophy (SMA) medicine Evrysdi only gained its FDA approval in 2020, but generics companies are already eying the blockbuster as a potential target.
By: Zoey Becker
While president-elect Donald Trump has already made his leadership picks for the Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS), a crucial spot for the biopharma industry remains open at the FDA.
By: Zoey Becker, Darren Incorvaia
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry.
By: Zoey Becker
For many biopharmas, it takes years of hard work to transition from being a clinical-stage drugmaker to a commercial one. Companies rarely want to make the shift back.
By: Zoey Becker
Before Exelexis' Cabometyx can pass muster with the FDA in its hopeful neuroendocrine tumors indication next April, it will have to first face the agency's Oncologic Drugs Advisory Committee (ODAC) in March 2025.
By: Zoey Becker
Robert F. Kennedy Jr.'s appointment last month to lead the U.S. Department of Health and Human Services immediately sent waves of speculation swirling throughout the biopharma industry.
(833) 317-6278 
